Abstract
This report analyzes the worldwide markets for Alzheimer' s and Parkinson' s
Disease in Millions of US$. The Major product segments Analyzed are
Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and
Anti-Parkinson' s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, &
Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine
Amplifiers). The report provides separate comprehensive analytics for the US,
Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for
each region for the period of 2000 through 2015. The report profiles 87
companies including many key and niche players worldwide such as Boehringer
Ingelheim, Bristol-Myers Squibb Co., Eisai Inc., Eli Lilly and Company, Forest
Pharmaceuticals, GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals
GMBH, Novartis AG, Ortho-McNeil Neurologics, Inc., Pfizer Inc., Roche, Shire
Pharmaceuticals Group PLC, and Valeant Pharmaceuticals International. Market
data and analytics are derived from primary and secondary research. Company
profiles are mostly extracted from URL research and reported select online
sources.